Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Preprint |
| Publicado: |
2022
|
| Materias: | |
| Acceso en línea: | https://arxiv.org/abs/2210.06228 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1866916288971931648 |
|---|---|
| author | Meyer, Elias Laurin Mesenbrink, Peter Di Prospero, Nicholas A. Pericàs, Juan M. Glimm, Ekkehard Ratziu, Vlad Sena, Elena König, Franz |
| author_facet | Meyer, Elias Laurin Mesenbrink, Peter Di Prospero, Nicholas A. Pericàs, Juan M. Glimm, Ekkehard Ratziu, Vlad Sena, Elena König, Franz |
| contents | Non-alcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and a disease with high unmet medical need. Platform trials provide great benefits for sponsors and trial participants in terms of accelerating drug development programs. In this article, we describe some of the activities of the EU-PEARL consortium (EU Patient-cEntric clinicAl tRial pLatforms) regarding the use of platform trials in NASH, in particular the proposed trial design, decision rules and simulation results. For a set of assumptions, we present the results of a simulation study recently discussed with two health authorities and the learnings from these meetings from a trial design perspective. Since the proposed design uses co-primary binary endpoints, we furthermore discuss the different options and practical considerations for simulating correlated binary endpoints. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2210_06228 |
| institution | arXiv |
| publishDate | 2022 |
| record_format | arxiv |
| spellingShingle | Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints Meyer, Elias Laurin Mesenbrink, Peter Di Prospero, Nicholas A. Pericàs, Juan M. Glimm, Ekkehard Ratziu, Vlad Sena, Elena König, Franz Applications Non-alcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and a disease with high unmet medical need. Platform trials provide great benefits for sponsors and trial participants in terms of accelerating drug development programs. In this article, we describe some of the activities of the EU-PEARL consortium (EU Patient-cEntric clinicAl tRial pLatforms) regarding the use of platform trials in NASH, in particular the proposed trial design, decision rules and simulation results. For a set of assumptions, we present the results of a simulation study recently discussed with two health authorities and the learnings from these meetings from a trial design perspective. Since the proposed design uses co-primary binary endpoints, we furthermore discuss the different options and practical considerations for simulating correlated binary endpoints. |
| title | Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints |
| topic | Applications |
| url | https://arxiv.org/abs/2210.06228 |